<?xml version="1.0" encoding="UTF-8"?>
<p id="Par50">To pay for health, countries in receipt of official development assistance are increasingly being asked to generate domestic funding [
 <xref ref-type="bibr" rid="CR43">43</xref>]. For viral hepatitis, the potential number of cases for prevention and treatment is enormous, yet the area is only slowly being recognized as a funding priority, although in most countries its financing will face an uphill struggle against established and new competitors for funding as well as constrained resources. While attention currently focuses on hepatitis C, hepatitis A, B, D and E must not be overlooked.
</p>
